|Day Low/High||3.39 / 3.50|
|52 Wk Low/High||1.88 / 4.06|
Piper Jaffray increased its price target on Rigel Pharma (RIGL) stock on Tuesday following a late-stage study win for an experimental drug.
Even concerns about a possible Fed rate hike do not appear to be affecting traders.
The 18% response rate for fostamatinib in the Rigel phase III study was on the lower end of investor expectations.
Conference call and webcast today at 8:00 AM Eastern Time
Trade-Ideas LLC identified Rigel Pharmaceuticals (RIGL) as a weak on high relative volume candidate
Elliott Grossbard, M.D. Retires; Continues Advising on Fostamatinib in the ITP Program
The most recent short interest data has been released by the NASDAQ for the 06/15/2015 settlement date, which shows a 355,726 share increase in total short interest for Rigel Pharmaceuticals Inc , to 2,855,027, an increase of 14.23% since 05/29/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
Trade-Ideas LLC identified Rigel Pharmaceuticals (RIGL) as a strong on high relative volume candidate
Investors considering a purchase of Rigel Pharmaceuticals Inc shares, but tentative about paying the going market price of $3.61/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the September put at the $2.50 strike, which has a bid at the time of this writing of 15 cents.